title: [Hepatorenal syndrome: diagnosis, treatment and prevention].
abstract: Cirrhosis, ascites and renal impairment are associated with high morbidity and mortality. The hepatorenal syndrome (HRS) is a type of renal failure that affects patients with cirrhosis and ascites. This paper provides an update on evidence-based interventions in HRS. A number of factors can precipitate HRS. The monitoring, prevention, early detection, and correct treatment of these are essential. Terlipressin combined with albumin is the first-line treatment of type 1 HRS. In type 2 HRS with refractory ascites, liver transplantation and TIPS should be considered.
authors.affiliation: Medicinsk Afdeling F, Gentofte Hospital, Denmark.
authors.forename: Mads
authors.initials: M
authors.lastname: Egerod Israelsen
authors.forename: Lise Lotte
authors.initials: LL
authors.lastname: Gluud
authors.forename: Flemming
authors.initials: F
authors.lastname: Bendtsen
authors.forename: Søren
authors.initials: S
authors.lastname: Møller
authors.forename: Aleksander Ahm
authors.initials: AA
authors.lastname: Krag
mesh_terms: D000418:Albumins / Q000627:therapeutic use; D001201:Ascites / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006530:Hepatorenal Syndrome / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008103:Liver Cirrhosis / Q000150:complications / Q000628:therapy; D016031:Liver Transplantation; D008236:Lypressin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D019168:Portasystemic Shunt, Transjugular Intrahepatic; D000077585:Terlipressin; D014662:Vasoconstrictor Agents / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000418:Albumins; D014662:Vasoconstrictor Agents; D008236:Lypressin; D000077585:Terlipressin